New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials
For the last half century, vitamin K antagonists (VKAs) have been used for treatment and prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. However, their fragile pharmacokinetics, need for routine laboratory monitoring and dose adjustments complicated t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Yong Chan Lee
2016-12-01
|
| Series: | The Korean Journal of Helicobacter and Upper Gastrointestinal Research |
| Subjects: | |
| Online Access: | http://www.helicojournal.org/journal/view.html?doi=10.7704/kjhugr.2016.16.4.178 |
| _version_ | 1818440742182322176 |
|---|---|
| author | Sung-Won Jang |
| author_facet | Sung-Won Jang |
| author_sort | Sung-Won Jang |
| collection | DOAJ |
| description | For the last half century, vitamin K antagonists (VKAs) have been used for treatment and prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. However, their fragile pharmacokinetics, need for routine laboratory monitoring and dose adjustments complicated the use of these drugs. Recently, new oral anticoagulants (NOACs) have overcome the limitation of VKA therapy and shows favorable outcomes and better safety, especially for patients with intracranial hemorrhage, both in phase III clinical trials and real-world registry. Currently available NOACs are one thrombin inhibitor, dabigatran, and three Xa inhibitors, rivaroxaban, apixaban, and edoxaban. This review covers the pharmacokinetics, published pivotal clinical trials, and dose adjustments in chronic kidney disease. The reimbursement criteria, discontinuation during elective surgical procedure, issues on reversal agents are also discussed. |
| first_indexed | 2024-12-14T18:17:11Z |
| format | Article |
| id | doaj.art-2b49d9467d6c4aa1bbb22e2f1af5cf2a |
| institution | Directory Open Access Journal |
| issn | 1738-3331 |
| language | English |
| last_indexed | 2024-12-14T18:17:11Z |
| publishDate | 2016-12-01 |
| publisher | Yong Chan Lee |
| record_format | Article |
| series | The Korean Journal of Helicobacter and Upper Gastrointestinal Research |
| spelling | doaj.art-2b49d9467d6c4aa1bbb22e2f1af5cf2a2022-12-21T22:52:10ZengYong Chan LeeThe Korean Journal of Helicobacter and Upper Gastrointestinal Research1738-33312016-12-0116417818410.7704/kjhugr.2016.16.4.178kjhugr.2016.16.4.178New Oral Anticoagulants: General Features and Review of Pivotal Clinical TrialsSung-Won Jang0Department of Internal Medicine, St. Paul’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, KoreaFor the last half century, vitamin K antagonists (VKAs) have been used for treatment and prevention of venous thromboembolism and stroke prevention in patients with atrial fibrillation. However, their fragile pharmacokinetics, need for routine laboratory monitoring and dose adjustments complicated the use of these drugs. Recently, new oral anticoagulants (NOACs) have overcome the limitation of VKA therapy and shows favorable outcomes and better safety, especially for patients with intracranial hemorrhage, both in phase III clinical trials and real-world registry. Currently available NOACs are one thrombin inhibitor, dabigatran, and three Xa inhibitors, rivaroxaban, apixaban, and edoxaban. This review covers the pharmacokinetics, published pivotal clinical trials, and dose adjustments in chronic kidney disease. The reimbursement criteria, discontinuation during elective surgical procedure, issues on reversal agents are also discussed.http://www.helicojournal.org/journal/view.html?doi=10.7704/kjhugr.2016.16.4.178ThrombinFactor XaAnticoagulantsAtrial fibrillationVenous thromboembolism |
| spellingShingle | Sung-Won Jang New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials The Korean Journal of Helicobacter and Upper Gastrointestinal Research Thrombin Factor Xa Anticoagulants Atrial fibrillation Venous thromboembolism |
| title | New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials |
| title_full | New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials |
| title_fullStr | New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials |
| title_full_unstemmed | New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials |
| title_short | New Oral Anticoagulants: General Features and Review of Pivotal Clinical Trials |
| title_sort | new oral anticoagulants general features and review of pivotal clinical trials |
| topic | Thrombin Factor Xa Anticoagulants Atrial fibrillation Venous thromboembolism |
| url | http://www.helicojournal.org/journal/view.html?doi=10.7704/kjhugr.2016.16.4.178 |
| work_keys_str_mv | AT sungwonjang neworalanticoagulantsgeneralfeaturesandreviewofpivotalclinicaltrials |